Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis

18 Apr 2013

Abstract excerpt

Visceral leishmaniasis (VL) is a vector-borne disease affecting humans and domestic animals that constitutes a serious public health problem in many countries. Although many antigens have been examined so far as protein- or DNA-based vaccines, none of them conferred complete long-term protection. The use of the lizard non-pathogenic to humans Leishmania (L.) tarentolae species as a live vaccine vector to deliver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Research on Leishmaniasis Studies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23638195
DOI: 10.1371/journal.pntd.0002174

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral LeishmaniasisPMID 23638195Read ↗

Immunization with a recombinant ASP-2/Transialidase chimeric protein induces robust protective immunity in both murine and canine models of Chagas’ diseaseSemantic proximity Read ↗

Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T Cells That Trigger Protection against Experimental Visceral LeishmaniasisSemantic proximity Read ↗

New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Trypanosoma cruzi CL-14 Strain Are Highly Antigenic and Protective against Leishmania infantum ChallengeSemantic proximity Read ↗

Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasiteSemantic proximity Read ↗

The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine CandidatesSemantic proximity Read ↗

Leishmaniasis: Current Status of Vaccine DevelopmentSemantic proximity Read ↗

Vaccine candidates, immuno-dominant antigens, and potent vaccine adjuvants for preventing cutaneous leishmaniasis: a sysSemantic proximity Read ↗

TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster ImmunizationSemantic proximity Read ↗

Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression hostSemantic proximity Read ↗

TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)Semantic proximity Read ↗

Immunization With a DNA Vaccine Cocktail Encoding TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 Genes Protects Mice Against Chronic ToxoplasmosisSemantic proximity Read ↗

Immunotherapeutic Potential of the Recombinant <em>Leishmania infantum</em> Eukaryotic Initiation Factor (LieIF) in Murine Experimental Models of LeishmaniasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.